Satellos Bioscience Inc. (MSLE) vs Veraxa Biotech AG (VRXA)

Satellos Bioscience Inc. and Veraxa Biotech AG are both Biotechnology companies. Satellos Bioscience Inc. and Veraxa Biotech AG are of similar size ($152.6M and $140.4M).

Valuation

Metric MSLE VRXA Biotechnology median
P/E n/m — 10.60
P/S n/m — 9.40
P/B 2.50 — 2.13
Price to free cash flow n/m — 25.18
EV/EBITDA n/m — 0.66
EV/Sales n/m — 9.02
Earnings yield (27.50%) — (32.88%)
Free cash flow yield (19.37%) — (23.13%)

Profitability

Metric MSLE VRXA Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% — 0.00%
Return on equity (70.45%) — (51.96%)
Return on assets (64.76%) — (46.06%)
Return on invested capital 0.00% — 0.00%

Growth

Metric MSLE VRXA Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 21.20% — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric MSLE VRXA Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 11.22 — 4.97
Net debt to EBITDA 1.05 — 1.01

Dividend

Metric MSLE VRXA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MSLE VRXA Biotechnology median
Market cap 152.57m 140.35m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack